NRIX: Nurix Therapeutics, Inc.
About
Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in the business of discovering, developing, and commercializing innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in San Francisco, CA.
Current Value
$22.571 Year Return
Current Value
$22.571 Year Return
Key Details
Market Cap
$1.61B
P/E Ratio
-7.83
1Y Stock Return
269.37%
1Y Revenue Growth
-17.76%
Dividend Yield
0.00%
Price to Book
4.1
Strategies that include NRIX
Stock's related to NRIX
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| BEAM | 46.32% | $2.09B | -9.52% | 0.00% |
| ALNT | 45.11% | $419.62M | -4.92% | 0.36% |
| SAFE | 42.98% | $1.47B | +9.32% | 3.47% |
| BLDP | 40.36% | $398.23M | -61.89% | 0.00% |
| ALEC | 40.34% | $377.04M | -19.46% | 0.00% |
| EDIT | 39.63% | $204.72M | -75.49% | 0.00% |
| SRI | 39.44% | $166.13M | -63.46% | 0.00% |
| AXL | 39.42% | $723.12M | -13.74% | 0.00% |
| IVR | 39.07% | $495.56M | +2.38% | 19.70% |
| LZB | 38.87% | $1.77B | +34.23% | 1.78% |
| LADR | 38.80% | $1.49B | +6.01% | 7.91% |
| BBIO | 38.79% | $4.26B | -20.38% | 0.00% |
| WASH | 38.65% | $628.84M | +39.42% | 5.76% |
| NTLA | 38.64% | $1.44B | -50.35% | 0.00% |
| ILPT | 38.61% | $253.33M | +31.62% | 1.05% |
| KYMR | 38.41% | $2.77B | +125.95% | 0.00% |
| FARO | 38.36% | $486.17M | +40.51% | 0.00% |
| NYMT | 38.22% | $538.04M | -30.85% | 13.54% |
| NFBK | 38.18% | $557.75M | +32.52% | 3.98% |
| HAFC | 38.18% | $767.29M | +55.13% | 3.93% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| ZCMD | 0.02% | $2.80M | -88.67% | 0.00% |
| XBIT | -0.13% | $203.32M | +87.36% | 0.00% |
| KR | -0.16% | $42.03B | +35.08% | 2.11% |
| ALL | 0.17% | $52.06B | +45.67% | 1.85% |
| GL | 0.19% | $9.18B | -8.60% | 0.86% |
| OCX | -0.19% | $42.93M | -36.09% | 0.00% |
| STNG | 0.24% | $2.96B | +0.87% | 2.75% |
| CHKP | 0.27% | $19.20B | +20.74% | 0.00% |
| STG | -0.27% | $35.67M | +7.92% | 0.00% |
| VSTA | 0.29% | $204.94M | -39.33% | 0.00% |
| WLKP | 0.40% | $796.39M | +4.00% | 8.34% |
| CNC | 0.43% | $29.19B | -21.56% | 0.00% |
| PEP | -0.46% | $215.02B | -6.60% | 3.35% |
| SOC | 0.47% | $1.93B | +74.70% | 0.00% |
| TH | -0.50% | $839.02M | -24.49% | 0.00% |
| TLRY | -0.55% | $1.18B | -26.40% | 0.00% |
| CLX | -0.64% | $20.81B | +20.66% | 2.88% |
| ACGL | -0.69% | $36.00B | +16.84% | 0.00% |
| FTNT | -0.69% | $69.59B | +72.67% | 0.00% |
| SBUX | 0.76% | $111.45B | -5.15% | 2.37% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CME | -15.84% | $82.76B | +9.21% | 1.98% |
| COR | -15.51% | $47.48B | +21.20% | 0.86% |
| MCK | -14.26% | $78.15B | +35.51% | 0.42% |
| CYCN | -13.42% | $4.77M | -16.19% | 0.00% |
| PULM | -11.54% | $19.83M | +202.98% | 0.00% |
| TEM | -10.94% | $8.50B | 0.00% | 0.00% |
| CHD | -10.58% | $27.18B | +19.50% | 1.03% |
| SYPR | -10.07% | $32.23M | -26.32% | 0.00% |
| NOC | -10.00% | $71.54B | +4.23% | 1.60% |
| LMT | -9.81% | $126.40B | +18.99% | 2.36% |
| CBOE | -9.43% | $21.46B | +15.84% | 1.11% |
| UNH | -8.92% | $531.00B | +6.93% | 1.37% |
| TCTM | -8.86% | $8.10M | -42.99% | 0.00% |
| MNR | -8.83% | $1.66B | -10.71% | 15.90% |
| LITB | -8.18% | $35.48M | -75.45% | 0.00% |
| NHTC | -7.92% | $61.83M | +0.19% | 14.81% |
| PGR | -7.35% | $149.10B | +57.29% | 0.45% |
| DOGZ | -7.22% | $614.77M | +1,372.26% | 0.00% |
| GAN | -6.92% | $83.39M | +21.19% | 0.00% |
| IMRN | -6.66% | $10.31M | -5.04% | 0.00% |
ETF's related to NRIX
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| USCI | 0.64% | $185.47M | 1.07% |
| XBIL | -0.81% | $637.70M | 0.15% |
| DBC | -1.50% | $1.39B | 0.87% |
| BSCO | 1.50% | $2.35B | 0.1% |
| TBIL | 1.57% | $4.38B | 0.15% |
| DUSB | 1.58% | $797.63M | 0.15% |
| DBA | -1.64% | $755.88M | 0.93% |
| KRBN | 1.68% | $242.47M | 0.85% |
| KCCA | 1.72% | $220.51M | 0.87% |
| JBBB | 1.74% | $1.26B | 0.49% |
| PDBC | -1.84% | $4.40B | 0.59% |
| SGOV | 2.14% | $27.53B | 0.09% |
| FLRN | -2.16% | $2.33B | 0.15% |
| SOYB | -2.19% | $27.32M | 0.22% |
| TPMN | 2.29% | $40.60M | 0.65% |
| FTGC | 2.30% | $2.17B | 1.02% |
| XHLF | 2.78% | $874.27M | 0.03% |
| GSG | -3.21% | $914.42M | 0.75% |
| DBMF | -3.23% | $1.02B | 0.85% |
| FLTR | 3.34% | $1.79B | 0.14% |
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTAL | -41.18% | $388.04M | 1.43% |
| CTA | -21.32% | $350.27M | 0.78% |
| VIXY | -19.05% | $195.31M | 0.85% |
| USDU | -16.82% | $201.97M | 0.5% |
| UUP | -13.89% | $309.25M | 0.77% |
| EQLS | -13.19% | $76.08M | 1% |
| CORN | -12.25% | $61.12M | 0.2% |
| KMLM | -9.54% | $353.87M | 0.9% |
| WEAT | -9.32% | $120.27M | 0.28% |
| DBO | -8.11% | $217.57M | 0.77% |
| AGZD | -6.36% | $142.76M | 0.23% |
| TAIL | -6.25% | $67.98M | 0.59% |
| DBE | -5.11% | $50.13M | 0.77% |
| MINT | -4.57% | $11.62B | 0.35% |
| CANE | -4.32% | $17.72M | 0.29% |
| CCOR | -3.90% | $109.04M | 1.18% |
| COMT | -3.89% | $829.06M | 0.48% |
| BILZ | -3.72% | $563.02M | 0.14% |
| DBMF | -3.23% | $1.02B | 0.85% |
| GSG | -3.21% | $914.42M | 0.75% |
News
Finnhub
The PRIME initiative provides enhanced support to developers of promising medicines to optimize development plans and accelerate evaluation Pivotal trials of NX-5948 are planned to initiate in 2025 ...
Yahoo
Data demonstrate potential superiority of a targeted protein degradation strategy compared to kinase inhibition for both BTK and IRAK4 targets in select inflammatory and autoimmune diseasesSAN FRANCISCO, Nov. 17, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced the presentation of preclinical data, including mec
Yahoo
SAN FRANCISCO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that data will be presented from its two Bruton’s tyrosine kinase (BTK) degrader programs, NX-5948 and NX-2127, in two oral presentations and one poster at the 66th American Society of Hematology Annual Meeting and Exposition being held Dec
Yahoo
SAN FRANCISCO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, Hans van Houte, chief financial officer of Nurix, and Jason Kantor, Ph.D., chief business officer of Nurix, will participate in the following conferences in
Finnhub
SAN FRANCISCO - Nurix Therapeutics, Inc. , a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases,...
Yahoo
Presentations will summarize new preclinical data from brain-penetrant, pan-mutant B-Raf degrader program and recent clinical data from NX-5948 BTK degrader program Members of the Nurix management team also to participate in several expert panel discussions SAN FRANCISCO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.